Novartis Not Nervous About SGLT2 Threat To Entresto

Cardiovascular Blockbuster Closing In On $4-$5bn Sales Guidance

 
• By Kevin Grogan
  
frontrunner
Novartis expects Entresto to continue setting the pace in heart failure • Source: Alamy
Scrip Podcast

Have you checked out Scrip podcast?

New episodes every Thursday.

SpotifyApple PodcastsWebsite

More from Cardiovascular

More from Therapeutic Category